Bhagiradha Chemicals & Industries Limited has informed the Exchange regarding 'Investors Presentation on the Financial Highlights for the quarter ended June 30, 2025'.
BHAGCHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bhagiradha Chemicals reported Q1FY26 revenue of Rs. 123.8 crore, up 11% YoY on strong double-digit volume growth, though price realizations remained weak. EBITDA fell 25% YoY to Rs. 9 crore and PAT dropped 30% to Rs. 4 crore as raw material costs did not ease in line with falling product prices, compressing gross margins to 33.5% (from 37.5%). On a sequential basis, results improved — EBITDA rose 48% QoQ and PAT swung back to a profit from a Q4FY25 loss. Management stated pricing has bottomed out and expects operating leverage to support margin recovery in coming quarters. Capex of ~Rs. 800 crore remains on track, with Phase 1 (~Rs. 385 crore) expected to be operational by September 2025 and full benefits reflecting in FY27. The company also launched a new herbicide product, Pinoxaden, this quarter.
Near-term numbers remain under pressure from weak pricing and elevated working capital costs, which is likely to cap upside in the stock. However, the management's outlook for margin recovery, pricing bottoming, and the large capex coming on stream could support a gradual re-rating if execution stays on track.